Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC
November 15th 2023
Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.